BAX/ELN/PFE/JNJ: The worst case for BAX—assuming Gammagard for AD ends up reaching the market—is having to pay a single-digit-% royalty for the patent in question, IMO. Even then, PFE/JNJ/ELN will have a tough time collecting in full insofar as the Gammagard product for existing indications will likely be indistinguishable from the Gammagard product for AD.
p.s. It sounds like ‘agedwardssucks’ considers ELN a world-class screw-up. All told, it’s hard to disagree.
BAX appears to be jinxed. They were the main target of the contaminated Chinese heparin in 2008, they botched the manufacturing of Gammagard IVIG and HALO’s Hylenex, and they recently had to write off $600M for an FDA recall of defective infusion pumps that BAX had still not fixed four years after the problem was discovered.
Now Greece says it doesn’t have the money to pay BAX for its antibodies and plasma proteins.
Nothing has gone wrong yet with BAX’s Alzheimer’s program, but it may be only a matter of time.
Market Data 
Markets 
AI
